Tupper Colleen 4

What Happened

• On 2026-02-10, Colleen Tupper, Chief Financial Officer of Collegium Pharmaceutical, was granted 26,421 restricted stock units (RSUs) and had 32,734 performance share units (PSUs) determined to be performance-vested. To satisfy withholding tax obligations on the vested awards, the issuer withheld 11,861 and 26,679 shares (total 38,540 shares) at $46.75 per share, resulting in amounts withheld of $554,502 and $1,247,243 respectively (total ~$1,801,745). The RSUs were granted at $0.00 (no purchase price).

Key Details

• Transaction date: 2026-02-10; Form 4 filed 2026-02-12 (appears timely).
• Awards: 26,421 RSUs (grant) and 32,734 PSUs (performance-vested) — total 59,155 award units.
• Withheld/disposed for taxes: 38,540 shares withheld at $46.75 each, total ~$1.80M (reported as code F — tax withholding).
• Shares owned after transaction: Not specified in the filing.
• Footnotes: F1 describes RSU vesting schedule (1/3 vests Feb 10, 2027; remainder in equal annual installments over two years). F2 confirms PSUs met performance criteria and vested. F3/F4 note shares were withheld by the issuer to satisfy tax withholding.

Context

• This was a compensation/vesting event (awards and performance vesting), not an open-market sale or purchase. The withheld shares reflect the company retaining shares to cover required taxes (a common cashless withholding practice), not an insider-initiated sale.